BioNTech/Pfizer and Moderna will dominate the Covid-19 vaccine market next year, generating a massive $93.2bn in combined sales, almost double the amount in 2021, according to new forecasts.
The bullish projections by Airfinity, a health data analytics firm, suggest the two messenger RNA jab producers will control three-quarters of the non-Chinese Covid-19 vaccine market in 2022. Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year.